Moderna Raises $3.0Bn in a Zero-Coupon Convertible Note Offering

Moderna, Inc. (NASDAQ: MRNA) completed a $3.0Bn offering of zero-coupon convertible senior notes on September 1, 2026, roughly two weeks after clinical data appeared to reset how the market values its oncology assets.  The deal launched at $2.0Bn and priced at $2.6Bn, reaching its final size only when the initial purchasers exercised their option in full, which suggests demand ran well ahead of what the company had contemplated.  The notes carry no coupon, mature in 2032 and convert at a premium of approximately 47.5%, terms that are available to relatively few issuers at any given moment.  Moderna appears to have treated the August repricing as a financing window rather than as a valuation to be defended, and it raised roughly six years of non-amortizing capital while that window was open.

Offering Overview

The notes were issued as $3,000,000,000 aggregate principal amount of 0.00% Convertible Senior Notes due 2032, in a private offering completed on September 1, 2026.  The initial purchasers’ $400MM option was exercised in full, which took the deal from its $2.6Bn pricing on August 27 to its final size.  The notes pay no regular interest, and the principal amount does not accrete.  They mature on March 1, 2032 and were sold only to qualified institutional buyers in reliance on Section 4(a)(2) and Rule 144A.

The initial conversion rate is 4.7487 shares per $1,000 principal amount, which equates to a conversion price of approximately $210.58 per share.  That level represents an approximately 47.5% premium to the $142.77 closing price on August 27, 2026.  The notes are not redeemable before September 6, 2029, after which any redemption is subject to a 130% price test, and they are convertible into 14,246,100 shares, rising to as many as 21,012,600 shares if antidilution and make-whole adjustments apply in full.  Moderna also entered capped call transactions on August 27 and August 28 with a cap price of approximately $392.62 per share, a 175% premium to the same reference price.  Net proceeds were approximately $2,957.3MM, and approximately $328.8MM of that amount was used to pay for the capped calls.

Use of Proceeds and Strategic Rationale

Moderna has said the net proceeds are for general corporate purposes, which may include the flexibility to invest in the growth of its oncology business and repayment of debt.  That language is deliberately broad, but the balance sheet suggests the raise was probably not a response to funding stress.  The company reported approximately $6.9Bn of cash, cash equivalents and investments at June 30, 2026 against roughly $591MM of long-term debt, a position that likely covers several years of the current burn without any new capital.  Issuers financing out of necessity generally accept whatever terms are available to them, while issuers financing out of preference are able to wait for a window of this kind.

Second-quarter revenue of approximately $145MM against a net loss of approximately $0.8Bn indicates that the respiratory franchise is no longer large enough to fund the pipeline on its own.  Oncology appears to be the most likely destination for the bulk of the proceeds.  Late-stage oncology development is expensive in a way that vaccine work at Moderna’s historical scale was not, and commercial preparation for an individualized therapy, including manufacturing, sequencing capacity and distribution logistics, probably requires committed spending well ahead of any approval.  Securing roughly six years of runway at a zero coupon appears to remove financing risk from that build-out, which may matter more to the company than the headline cost of the capital.

Market Context

The timing of the offering follows directly from what happened to the equity in August.  Shares closed at $62.96 on August 18, 2026 and rose very sharply over the following sessions after Moderna and its partner reported that intismeran autogene, an individualized neoantigen therapy, had met its primary endpoint of recurrence-free survival in a Phase 3 adjuvant melanoma trial enrolling roughly 1,137 patients.  By the August 27 pricing reference, the stock had settled at $142.77, still a multiple of where it traded before the report.  Issuing into that window allowed Moderna to set a conversion price above $210 per share, a level the stock had not approached at any point earlier in 2026.

The capped call transactions extend the same logic.  At approximately $392.62 per share, the effective economic conversion price sits at a 175% premium, and the approximately $328.8MM cost represents roughly 11% of principal.  Moderna appears to have concluded that paying that premium in cash today was preferable to accepting dilution at $210.58 per share should the oncology program perform.  That is a reasonably confident position for a company whose revenue base is currently contracting, and it is consistent with management treating the August repricing as durable rather than temporary.

Broader Implications for Biotech Financing

Convertible issuance has been running at an unusual pace.  U.S. issuers raised approximately $85.5Bn across 127 transactions through early June 2026, measured against a 2025 full-year record of roughly $140.5Bn, and healthcare issuers accounted for approximately $6.6Bn across 26 deals over the same period.  Zero-coupon structures paired with high conversion premiums have been available to issuers whose shares carry meaningful implied volatility, because convertible buyers are compensated by the embedded optionality rather than by income expectations.  Biotechnology equities such as Moderna tend to supply that volatility, and a share price that has just been repriced upward by clinical data supplies a prospective issuer with a strong motivation to act.

For other developers, the sequencing here is probably the most transferable element.  A clinical result repriced the equity, the company came to market within roughly a week, and the offering converted a change in sentiment into permanent, non-amortizing, non-cash-paying capital before that sentiment could be tested again.  Companies with a binary catalyst on the calendar may benefit from having documentation and structure prepared in advance, rather than beginning the process after the data readout.  Windows of this kind have not historically stayed open for long.

Conclusion

Moderna has raised $3.0Bn at a zero cash coupon, at a 47.5% conversion premium and with a hedged effective strike of approximately $392.62 per share, roughly two weeks after a Phase 3 readout that appears to have changed how the market values its oncology assets.  The full exercise of the $400MM option and the move from a $2.0Bn size at launch to a $3.0Bn size at closing suggest that demand comfortably exceeded what the company initially contemplated.  Whether the capital proves well spent will depend on the oncology program rather than on the financing, but the financing has likely removed the question of whether that program can be funded through to approval.  In a sector where the availability of capital often determines which programs advance and which are shelved, a financing window of this quality is worth noting when it opens.

About DelMorgan & Co. (www.delmorganco.com)

With over $300 billion of successful transactions in over 80 countries, DelMorgan’s Investment Banking professionals have worked on some of the most challenging, most rewarding and highest profile transactions in the U.S. and around the globe.  DelMorgan specializes in capital raising and M&A advisor services for companies across all industries and is recognized as one of the leading investment banking practices in California and globally.

Learn more about DelMorgan’s Capabilities, Transactions, and why DelMorgan is ranked as the #1 Investment Bank in Los Angeles and #2 in California by Axial.